

Faron Pharmaceuticals - Positive phase II BEXMAB topline results

Redeye comments on Faron's announcement that the phase II BEXMAB trial has met its primary endpoint in treatment-resistant high-risk MDS. We are encouraged to see topline results confirming earlier interim data, with sustained high response rates in this difficult-to-treat population and a continued strong safety profile. These findings not only validate bexmarilimab's clinical potential but also support Faron's regulatory and commercial strategy as the company prepares for pivotal phase III development.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Faron Pharmaceuticals - Positive phase II BEXMAB topline results